Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Pilot Program Will Speed U.S. Entry Of Drugs With Secure Supply Chains

Executive Summary

FDA is developing an implementation plan for pilot testing a program to speed entry into the U.S. of drugs that flow through a strong supply chain.

You may also be interested in...



Track-and-Trace Deal’s Failure Leaves California In Control Of Agenda

Industry groups will continue to search for legislative vehicles to move a national standard that would preempt state laws; near-term, though, manufacturers and distributors must prepare for California pedigree law.

PDUFA Stars Aligning As House Draft Gives FDA Direct Authority Over Importers

Latest version of potential House user fee bill eliminates revisions to FDA’s mission statement and includes provisions for approving breakthrough technologies and destroying unsafe drug imports at the border.

What’s In A PDUFA Reauthorization? Maybe These Issues…

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS053702

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel